AR006202A1 - Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene - Google Patents

Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene

Info

Publication number
AR006202A1
AR006202A1 ARP970100986A ARP970100986A AR006202A1 AR 006202 A1 AR006202 A1 AR 006202A1 AR P970100986 A ARP970100986 A AR P970100986A AR P970100986 A ARP970100986 A AR P970100986A AR 006202 A1 AR006202 A1 AR 006202A1
Authority
AR
Argentina
Prior art keywords
prepare
treatment
ige
ige antagonist
compositions containing
Prior art date
Application number
ARP970100986A
Other languages
English (en)
Spanish (es)
Original Assignee
Univ Johns Hopkins
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Genentech Inc filed Critical Univ Johns Hopkins
Publication of AR006202A1 publication Critical patent/AR006202A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP970100986A 1996-03-12 1997-03-12 Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene AR006202A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61422096A 1996-03-12 1996-03-12

Publications (1)

Publication Number Publication Date
AR006202A1 true AR006202A1 (es) 1999-08-11

Family

ID=24460327

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970100986A AR006202A1 (es) 1996-03-12 1997-03-12 Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene

Country Status (8)

Country Link
EP (1) EP0904108A1 (xx)
JP (1) JP2001505181A (xx)
AR (1) AR006202A1 (xx)
AU (1) AU726143B2 (xx)
CA (1) CA2246427A1 (xx)
IL (1) IL126113A0 (xx)
WO (1) WO1997033616A1 (xx)
ZA (1) ZA971607B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
AU2065801A (en) * 1999-12-06 2001-06-12 Panacea Pharmaceuticals, Llc Passive desensitization
GB0016441D0 (en) 2000-07-04 2000-08-23 Pharmagene Lab Limited Therapeutic method
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
AU2002316887A1 (en) * 2001-05-03 2002-11-18 Novartis Ag Anti-ige antibody to treat ocular allergies
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
CN114028569B (zh) * 2021-12-20 2023-04-28 中国医学科学院基础医学研究所 免疫球蛋白IgE在诊断和/或治疗高血压中的用途
CN114504644B (zh) * 2021-12-24 2024-02-13 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US4940715A (en) * 1988-05-17 1990-07-10 Kissei Pharmaceutical Co., Ltd. 5H-pyrazolo[4,3-A] quinolizin-5-one compounds exhibiting therapeutic activities
JP3156237B2 (ja) * 1991-12-24 2001-04-16 雪印乳業株式会社 抗ヒトＩｇＥ モノクローナル抗体

Also Published As

Publication number Publication date
CA2246427A1 (en) 1997-09-18
IL126113A0 (en) 1999-05-09
AU726143B2 (en) 2000-11-02
JP2001505181A (ja) 2001-04-17
ZA971607B (en) 1998-08-25
AU1987597A (en) 1997-10-01
EP0904108A1 (en) 1999-03-31
WO1997033616A1 (en) 1997-09-18

Similar Documents

Publication Publication Date Title
DE69027216D1 (de) Transmukosale dosisform
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
DE69230112T2 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ATE94393T1 (de) Dosisform zur oralen verabreichung des hypoglykaemischen glipizids.
KR101900520B1 (ko) 복합 조성물
ATE92762T1 (de) Medikamente.
MX173567B (es) Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih
Ryan et al. Experiences in the treatment of Paget's disease of bone with mithramycin
NZ225242A (en) Pad printing process for manufacturing a pharmaceutical presentation and/or dosage form for active ingredients of drugs
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
ES2139842T3 (es) Uso de la melatonina para tratar a pacientes que sufren drogodependencia.
AR006202A1 (es) Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
KR890006227A (ko) 페놀-함유 진해성 액체 조성물
ES2115571T3 (es) Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas.
JPH01261334A (ja) アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法
KR890004705A (ko) 항바이러스성 제제
JPS6360940A (ja) 白内障の予防または治療剤
AR002727A1 (es) El uso de ridogrel para la fabricacion de un medicamento util para el tratamiento de enfermedades digestivas inflamatorias, una composicionfarmaceutica que comprende ridogrel y un procedimiento para preparar dicha composicion.
ES2038847T3 (es) Proceso para la preparacion de una composicion farmacutica conteniendo zidovudine e inosiplex para el tratamiento del sida y sindromes afines.
ES2211594T3 (es) Medicamentos que contienen acido pantotenico para el tratamiento de enfermedades inflamatorias de las articulaciones.
EP0402208B1 (fr) Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique